Achilles Therapeutics Past Earnings Performance
Past criteria checks 0/6
Achilles Therapeutics's earnings have been declining at an average annual rate of -22.8%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-22.8%
Earnings growth rate
64.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -64.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Achilles Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -67 | 16 | 56 |
| 30 Jun 24 | 0 | -64 | 16 | 54 |
| 31 Mar 24 | 0 | -64 | 16 | 54 |
| 31 Dec 23 | 0 | -70 | 17 | 58 |
| 30 Sep 23 | 0 | -75 | 17 | 54 |
| 30 Jun 23 | 0 | -71 | 18 | 50 |
| 31 Mar 23 | 0 | -71 | 20 | 51 |
| 31 Dec 22 | 0 | -71 | 21 | 50 |
| 30 Sep 22 | 0 | -65 | 24 | 50 |
| 30 Jun 22 | 0 | -66 | 23 | 50 |
| 31 Mar 22 | 0 | -65 | 23 | 46 |
| 31 Dec 21 | 0 | -61 | 22 | 42 |
| 30 Sep 21 | 0 | -56 | 19 | 39 |
| 30 Jun 21 | 0 | -51 | 17 | 34 |
| 31 Mar 21 | 0 | -42 | 14 | 28 |
| 31 Dec 20 | 0 | -33 | 11 | 23 |
| 30 Sep 20 | 0 | -25 | 9 | 16 |
| 30 Jun 20 | 0 | -19 | 7 | 12 |
| 31 Mar 20 | 0 | -16 | 5 | 10 |
| 31 Dec 19 | 0 | -14 | 5 | 9 |
Quality Earnings: 698 is currently unprofitable.
Growing Profit Margin: 698 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 698 is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.
Accelerating Growth: Unable to compare 698's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 698 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 698 has a negative Return on Equity (-64.84%), as it is currently unprofitable.